China Isotope & Radiation Corporation

HKSE 1763.HK

China Isotope & Radiation Corporation Return on Assets (ROA) for the year ending December 31, 2023: 2.81%

China Isotope & Radiation Corporation Return on Assets (ROA) is 2.81% for the year ending December 31, 2023, a -16.23% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

China Isotope & Radiation Corporation Return on Assets (ROA) for the year ending December 31, 2022 was 3.36%, a 4.72% change year over year.
China Isotope & Radiation Corporation Return on Assets (ROA) for the year ending December 31, 2021 was 3.21%, a 37.86% change year over year.
China Isotope & Radiation Corporation Return on Assets (ROA) for the year ending December 31, 2020 was 2.33%, a -37.50% change year over year.
China Isotope & Radiation Corporation Return on Assets (ROA) for the year ending December 31, 2019 was 3.72%, a -20.91% change year over year.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

HKSE: 1763.HK

China Isotope & Radiation Corporation

CEO	Mr. Junqi Zhang
IPO Date	July 6, 2018
Location	China
Headquarters	No. 66 Changwa Middle Street
Employees	3,132
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China. It operates through five segments: Pharmaceuticals; Radioactive Source Products; Irradiation; Radiation Therapy Equipment and Related Services; and Independent Clinical Medical and Laboratory Services, and Other Business. The Pharmaceuticals segment engages in the research, development, manufacture, and sale of imaging diagnostic and therapeutic radiopharmaceuticals; UBT kits and analyzers; and in vitro immunoassay diagnostic reagents and kits. The Radioactive Source Products segment provides medical and industrial radioactive sources products and related technical services. The Irradiation segment offers irradiation services to manufacturers of medical devices, food, traditional Chinese medicine, and cosmetics for sterilization; and EPC services for the design, manufacturing, and installation of gamma ray irradiation facilities. The Radiation Therapy Equipment and Related Services segment sells radiation therapy equipment; and provides related maintenance services. The Independent Clinical Medical and Laboratory Services, and Other Business segment provides independent clinical laboratory services with respect to hepatitis, endocrine, bone metabolism, cardiovascular disease, diabetes, and other diseases to hospitals and other medical institutions. The company was founded in 1983 and is headquartered in Beijing, China. China Isotope & Radiation Corporation is a subsidiary of China National Nuclear Corporation.

Key trends

Past 5 years